title: [Leukemia and pre-leukemic conditions occurring after treatment of breast cancer].
abstract: OBJECTIVE
  The purpose of this study was to determine the clinical and prognostic features of leukemias and preleukemic states, whatever the mode of development, observed in patients after treatment of breast cancer.
  
  
  METHODS
  A retrospective multicentric analysis was made of 121 patients treated for breast cancer and who later developed leukemia or a preleukemic state. Initially, 44 patients had undergone mastectomy, 72 had conservative surgery and 119 had locoregional irradiation. At least one chemotherapy session was performed in 90 patients and 48 had received tamoxifen. The risk of relapse of breast cancer was high, moderate or low for 44, 46 and 24 patients respectively (data not available for 7 patients).
  
  
  RESULTS
  By class, the hematology diseases found were: myelodysplasia (n = 9), refractory anemia with blast excess (n = 7), acute lymphoblastic leukemia (n = 6), acute myoblastic leukemia (n = 93 including a majority of type 2 and type 4). For acute myeloblastic leukemia, mean delay to onset was 65 and 37 months respectively without and after chemotherapy. The prognosis of these cases of leukemia and preleukemic states was poor with an overall death rate of 86%.
  
  
  CONCLUSIONS
  In light of the recent development of indications for adjuvant chemotherapy even for subgroups of patients at moderate risk, it is important to more precisely assess the absolute benefit in terms of survival compared with the risk of severe complications, particular secondary leukemia. In the future, a systematic registry and a case-control study are required.
authors.affiliation: Centre de Radiothérapie et d'Oncologie Médicale, Clinique de Courlancy, Reims.
authors.forename: B
authors.initials: B
authors.lastname: Cutuli
authors.forename: M
authors.initials: M
authors.lastname: Janvier
authors.forename: A
authors.initials: A
authors.lastname: de la Rochefordière
authors.forename: J P
authors.initials: JP
authors.lastname: Julien
authors.forename: N
authors.initials: N
authors.lastname: Isambert
authors.forename: C
authors.initials: C
authors.lastname: Alzieu
authors.forename: P
authors.initials: P
authors.lastname: Kerbrat
authors.forename: B
authors.initials: B
authors.lastname: de Lafontan
authors.forename: L
authors.initials: L
authors.lastname: van Lemmens
authors.forename: H
authors.initials: H
authors.lastname: Curé
authors.forename: G
authors.initials: G
authors.lastname: Ganem
authors.forename: D
authors.initials: D
authors.lastname: Baume
authors.forename: A
authors.initials: A
authors.lastname: Le Mevel
authors.forename: A
authors.initials: A
authors.lastname: Lorthoraly
authors.forename: C
authors.initials: C
authors.lastname: de Gislain
authors.forename: C
authors.initials: C
authors.lastname: Marchal
authors.forename: C
authors.initials: C
authors.lastname: Chevelle
authors.forename: H
authors.initials: H
authors.lastname: Lauche
authors.forename: D
authors.initials: D
authors.lastname: Serin
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007938:Leukemia / Q000209:etiology*; D008408:Mastectomy; D008875:Middle Aged; D009436:Neural Tube Defects / Q000209:etiology*; D011183:Postoperative Complications; D011289:Preleukemia / Q000209:etiology*; D012189:Retrospective Studies